Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland.

Medtronic plc.

Median Technologies ( ($FR:ALMDT) ) has shared an update. Median Technologies, a specialist in AI-based medical imaging software and central imagin...

Median Technologies strengthens finances as eyonis lung cancer AI wins U.S. and EU approval

Shares in medical group Johnson & Johnson ($JNJ) were healthier today after it received the green light to begin the “next era” of robotic surgery....

Johnson & Johnson Continues Recovery After Green Light Given to ‘Next Era’ Robotic Surgeon

The approval opens a new market for the healthcare company. 


Johnson & Johnson Stock (JNJ) Rises as Robotic Surgery Device Is Approved

RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Medtronic yesterday and set a price target of $118.00. Singh Chadha covers the H...

Medtronic (MDT) Gets a Buy from RBC Capital

Citi analyst Joanne Wuensch reiterated a Buy rating on Medtronic on July 6 and set a price target of $110.00. The company’s shares closed yesterday...

Medtronic (MDT) Receives a Buy from Citi

Electrolux AB ( ($SE:ELUX.B) ) has issued an update. AB Electrolux has completed a previously announced rights issue of Class A and Class B shares,...

Electrolux Reshapes Share Capital Structure After Major Rights Issue

Electrolux AB ( ($SE:ELUX.B) ) just unveiled an announcement. Electrolux Group has issued a supplement to its previously published rights issue pro...

Electrolux updates rights issue prospectus after filing USD 88m tariff refund claims

Electrolux AB ( ($SE:ELUX.B) ) has issued an announcement. Electrolux Group has submitted refund claims under the U.S. IEEPA tariff refund program,...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MDT	$83.17	+1.41%	1.89M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MDT	$83.17	+1.4%	1.89M
3
4
5
6

MDT

MDT

Get Medtronic plc. Data in Excel

Get Medtronic plc. Data in Excel